Amphastar P Asset Resilience Ratio

Latest as of June 2026: 3.81%

Amphastar P asset resilience ratio. Amphastar P (AMPH) has an Asset Resilience Ratio of 3.81% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Amphastar P defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$66.51 Million
Cash + Short-term Investments

Total Assets

$1.74 Billion
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Amphastar P (2012–2025)

Asset resilience ratio of Amphastar P from 2012 to 2025. This chart shows how Amphastar P's Asset Resilience Ratio has changed over time. Read Amphastar P debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Amphastar P's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see AMPH current and non-current assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $66.51 Million 3.81%
Total Liquid Assets $66.51 Million 3.81%

Asset Resilience Insights

  • Limited Liquidity: Amphastar P maintains only 3.81% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Amphastar P Industry Peers by Asset Resilience Ratio

Compare Amphastar P's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
Drug Manufacturers - Specialty & Generic 0.16%
Sandoz Group AG
SW:SDZ
Drug Manufacturers - Specialty & Generic 7.89%
H Lundbeck A/S
CO:HLUN-B
Drug Manufacturers - Specialty & Generic -0.56%
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 5.50%
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
Drug Manufacturers - Specialty & Generic 47.16%
Kangmei Pharmaceutical Co Ltd
SHG:600518
Drug Manufacturers - Specialty & Generic 0.00%
Viyash Scientific Limited
NSE:SEQUENT
Drug Manufacturers - Specialty & Generic 0.08%
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
Drug Manufacturers - Specialty & Generic 1.81%

Amphastar P Asset Resilience Ratio by Year (2012–2025)

Amphastar P asset resilience ratio by year from 2012 to 2025. The table below shows the annual Asset Resilience Ratio data for Amphastar P.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 6.91% $112.64 Million $1.63 Billion +2.47pp
2024-12-31 4.44% $70.04 Million $1.58 Billion -3.00pp
2023-12-31 7.44% $112.51 Million $1.51 Billion +4.79pp
2022-12-31 2.65% $19.66 Million $741.99 Million +1.11pp
2021-12-31 1.54% $10.32 Million $671.53 Million -0.52pp
2020-12-31 2.06% $12.98 Million $631.24 Million -0.32pp
2019-12-31 2.38% $13.96 Million $586.97 Million +1.83pp
2018-12-31 0.55% $2.83 Million $513.56 Million -0.03pp
2017-12-31 0.58% $2.63 Million $454.67 Million +0.46pp
2016-12-31 0.12% $527.00K $427.74 Million -0.21pp
2015-12-31 0.33% $1.28 Million $390.14 Million -0.05pp
2014-12-31 0.38% $1.50 Million $389.37 Million -0.01pp
2013-12-31 0.39% $1.32 Million $338.75 Million -0.20pp
2012-12-31 0.59% $1.89 Million $317.48 Million --
pp = percentage points

About Amphastar P

NASDAQ:AMPH USA Drug Manufacturers - Specialty & Generic
Market Cap
$1.19 Billion
Market Cap Rank
#8705 Global
#2523 in USA
Share Price
$28.02
Change (1 day)
+3.32%
52-Week Range
$16.87 - $29.40
All Time High
$65.00
About

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mi… Read more